Aspirin-Exacerbated Respiratory Disease Polymorphisms; a review study
Aida Fathollahpour1, Fahimeh Abdi Abyaneh2, Behzad Darabi3
1Iran Universuty of Medical Science, Tehran, Iran.
Gene
|April 3, 2023
Summary
Genetic factors influencing Aspirin Exacerbated Respiratory Disease (AERD) are complex. Identifying common gene variants may aid in diagnosing and treating AERD, a condition linked to asthma and NSAID sensitivity.
Area of Science:
- Genetics
- Immunology
- Respiratory Medicine
Background:
- Aspirin Exacerbated Respiratory Disease (AERD) involves bronchoconstriction after NSAID use in asthma patients.
- The genetic underpinnings of AERD remain largely unknown.
- Human genome analysis offers insights into genetic polymorphisms and disease susceptibility.
Purpose of the Study:
- To identify genetic factors influencing Aspirin Exacerbated Respiratory Disease (AERD).
- To explore the association between gene polymorphisms and AERD.
- To provide a basis for improved AERD diagnosis and treatment.
Main Methods:
- Systematic review of research studies, letters, comments, editorials, eBooks, and reviews.
- Searches conducted in PubMed/MEDLINE, Web of Sciences, Cochrane Library, and Scopus.
- Keywords included polymorphisms, aspirin-exacerbated respiratory disease, asthma, and allergy.
Main Results:
- Thirty-eight studies were included in the analysis.
- AERD complications were associated with polymorphisms in numerous genes, including ALOX15, EP2, ADRB2, and various HLA types.
- Significant heterogeneity in gene polymorphisms complicates the identification of specific causative genetic changes.
Conclusions:
- AERD is linked to a complex interplay of gene polymorphisms.
- The heterogeneity observed makes pinpointing single genetic factors challenging.
- Examining common gene variants associated with AERD may facilitate diagnosis and treatment strategies.
Related Concept Videos
01:05Single Nucleotide Polymorphisms-SNPs
A single nucleotide polymorphism or SNP is a single nucleotide variation at a specific genomic position in a large population. It is the most prevalent type of sequence variation found in the human genome. Point mutations that occur in more than 1% of the population qualify as SNPs. These are present once every 1000 nucleotides on an average in the human genome. Replacement of a purine with another purine (A/G) or a pyrimidine with another pyrimidine (C/T) is known as a transition. In contrast,...
01:27Principles of Pharmacogenetics: Types of Genetic Variants
The human genome is over 99.9% identical between individuals, yet genetic differences exist at millions of bases. The human genome contains approximately 3 million variant positions per individual, many of which are heterozygous, contributing to genetic diversity and individual traits. Genetic variations include single-nucleotide polymorphisms (SNPs), insertions, deletions, and copy number variations (CNVs).SNPs, the most common variation, involve single-base changes in DNA. These can be...
01:29Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu
Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
01:27Pharmacogenetics of Drug Metabolism: Overview
Genetic polymorphism in drug metabolism is crucial to the inter-individual variability observed in drug responses. Drug metabolism primarily involves the chemical modification of drugs and other xenobiotics to enhance their elimination by increasing their polarity. Two main classes of enzymes mediate this biotransformation process: Phase I enzymes, primarily cytochrome P450s, catalyze oxidation and reduction reactions, while other enzymes, such as esterases, mediate hydrolysis, and Phase II...
01:27Pharmacogenetics of Phase II Enzymes: N-acetyltransferase, Thiopurine S-methyltransferase, UDP-glucuronosyltransferase
Phase II biotransformation reactions are essential for detoxifying and eliminating xenobiotics, including many pharmaceutical compounds. These reactions typically involve conjugation, the covalent attachment of polar endogenous groups such as glucuronic acid, sulfate, methyl, or acetyl moieties to functional groups introduced during Phase I metabolism. The resulting conjugates are more water-soluble, enabling efficient renal or biliary excretion.The major classes of Phase II enzymes include...
01:11Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...